Redundancies at Alfasigma, garrison in Milan

Il nuovo gruppo farmaceutico italiano annuncia 456 licenziamenti (su 1.626 dipendenti). Zago (Filctem Cgil): “Il progetto industriale non può fare a meno di tutte quelle valide competenze che hanno determinato finora i risultati positivi dell’azienda”

28 settembre 2017 – rassegna.it

Sciopero nazionale e presidio oggi (giovedì 28 settembre) a Milano dei lavoratori dell’azienda farmaceutica Alfasigma. L’appuntamento è sotto la sede di Assolombarda, in occasione della ripresa delle trattative per i 456 licenziamenti (su 1.626 dipendenti). The decision came on 6 September last, when the new industrial plan was communicated, which precisely provides for the need for a reorganization based on redundancies.

"The objective of the negotiation is to modify the serious organizational decisions taken by the company, which heavily affect many workers". To say it is Aldo Zago, of the Pharmaceutical Chemical Department of the national Filctem Cgil: "The industrial project of this new pharmaceutical group cannot do without all those valid skills that have determined, up to now, the positive results of the company". The cuts, in particular, should affect 274 scientific computer scientists and 182 administrative employees (of which 138 in the former Sigma Tau headquarters in Pomezia, in Rome) divided into all company offices.

La Alfasigma riunisce in un’unica società alcuni tra i maggiori gruppi farmaceutici nazionali, con capitale totalmente italiano (75 percent of the company belongs to the Golinelli family). It is currently the third company in the sector, its turnover exceeds one billion euros. It is also a newborn company: in fact, it was formed on 1st August through the merger of Alfa Wassermann, Biofutura Pharma and Sigma-Tau Industrie Farmaceutiche Riunite. The production sites are in Alanno (Pescara), Sermoneta (Latina) and Pomezia (Rome), the administrative office is in Bologna and the legal office in Milan (which also coordinates the scientific information activity of the drug).

Le motivazioni addotte dall’azienda, si legge in una interrogazione parlamentare del deputato Pd Marco Miccoli, sono state: “la dimensione critica in termini finanziari e dell’assetto produttivo per poter agire nel complesso contesto competitivo globale; il lieve decremento del mercato farmaceutico nel canale retail, nel quale si concentra il fatturato alphasigma; national pharmaceutical spending 30 percent lower than in other large European countries; the containment of expenditure in the sector, as for example in the revision of the formulary which took place in 2015; the duplication of some professional figures which was determined by the definitive maxi-merger”.

Related news: Alfasigma layoffs. Questions to the Chambers

Alfasigma mobility statement

ALFASIGMA, dismissal procedure started for 456 workers, 274 scientific representatives